Abstract:371 Background: Sunitinib, a multitargeted receptor tyrosine kinase inhibitor represents a standard firstline therapy for advanced renal cell carcinoma. Red blood cell (RBC) macrocytosis (with or without anaemia) is a recognized haematological toxicity but its aetiology remains uncertain. METHODS The medical records of 73 patients (55 male, 18 female) patients treated with sunitinib between 2007 and 2010 at Poole and Bournemouth NHS Trusts, UK were reviewed. Patient demographics, length of treatment, response, RBC mean cell volume (MCV) indices, and known causes of macrocytosis including B12 and folate deficiency and hypothyroidism were examined. RESULTS Median duration of treatment was 6 months (range 0-30). 38 (51%) have died. 24 (32%) received 2 or less cycles of treatment with the majority stopping due to early progression or death. 30 patients (41%) developed macrocytosis on treatment, but a trend to macrocytosis was identified in most patients positively correlating to time on treatment. 26 (87%) had a macrocytic anaemia. Median time to onset of macrocytosis was 4 months (range 1-11 months). Of the 30 macrocytic patients; 5 were hypothyroid, 7 had untreated borderline hypothyroidism and 13 were euthryoid throughout. Of patients tested to date 1 patient was found to be serum folate deficient at 2.5 ug/L (3-17). Supplementation corrected the macrocytosis. 1 patient was found to be serum B12 deficient; 53 ng/L (180-900) without any obvious comorbid cause. Further retrospective evaluation of other parameters such as red cell folate and reticulocyte count are currently being carried out. CONCLUSIONS A significant proportion of patients on sunitinib (41%) develop macrocytosis. On the basis of this case series, the largest to date, underlying causes of macrocytosis (with or without anaemia) appear multifactorial. Biochemical hypothyrodism is common following sunitinib treatment and is likely to represent one of several possible contributing factors. B12 and folate deficiency should not be forgotten as a potentially reversible cause of macrocytosis secondary to sunitinib. C-kit inhibition by sunitinib is a potential mechanism, paralleling the potential C-kit mediated macrocytosis commonly recognised in imatinib therapy. No significant financial relationships to disclose.

Involvement of mineralocorticoid receptor in high glucose-induced big mitogen-activated protein kinase 1 activation and mesangial cell proliferation

Immune regulation within the central nervous system

Diagnosis of congenital tracheoesophageal fistula in the adolescent and adult.

Guardians of CNS Homeostasis

CNS and CNS Diseases in Relation to Their Immune System

Immune cell compartmentalization for brain surveillance and protection

Cross-Talk of the CNS With Immune Cells and Functions in Health and Disease

Meningeal Immunity and Neurological Diseases: New Approaches, New Insights

[Non-A, non-B viral hepatitis: occurrence, epidemiology and prognosis].

Widespread occurrence of AP in amyloidotic tissues

The role of peripheral immune cells in the CNS in steady state and disease

Imaging of brain barrier inflammation and brain fluid drainage in human neurological diseases

An underinvestigated toxicity of sunitinib: Red cell macrocytosis.

Immune cells as messengers from the CNS to the periphery: the role of the meningeal lymphatic system in immune cell migration from the CNS

Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing Regulates Quality of Processed Peptides Presented by MHC Class I Molecules1

The Immune System in Neurological Diseases: What Innate-like T Cells have to Say

Mechanisms of myeloid cell entry to the healthy and diseased central nervous system

Role of meningeal immunity in brain function and protection against pathogens

Meningeal Lymphatics: From Anatomy to Central Nervous System Immune Surveillance

Living on the border of the CNS: Dural immune cells in health and disease

The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases